2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Brain Neoplasms
12
Cognitive Dysfunction
4
Radiation Injuries
3
Neoplasms
3
Multiple Myeloma
3
Glioma
3
Breast Neoplasms
3
Lymphoma, B-Cell
2
Lymphoma
2
Glioblastoma
2
Fatigue
2
Colorectal Neoplasms
2
Astrocytoma
2
Triple Negative Breast Neoplasms
1
Stroke
1
Sarcoma
1
Prostatic Neoplasms
1
Pituitary Neoplasms
1
Parkinson Disease
1
Osteosarcoma
1
Oligodendroglioma
1
Neurotoxicity Syndromes
1
Neurofibromatosis 1
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Meningioma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Interventions
siltuximab
4
tocilizumab
3
fludarabine
3
Cyclophosphamide
3
fludarabine phosphate
2
Interleukin 1 Receptor Antagonist Protein
2
AP 1903 reagent
2
talquetamab
1
otelixizumab
1
obinutuzumab
1
lopinavir-ritonavir drug combination
1
glofitamab
1
axicabtagene ciloleucel
1
Piperacillin, Tazobactam Drug Combination
1
Oxygen Inhalation Therapy
1
Oxaliplatin
1
Neuropsychological Tests
1
Metoprolol
1
Methylprednisolone
1
Magnetic Resonance Spectroscopy
1
Lopinavir
1
Leukapheresis
1
Infliximab
1
Hydroxychloroquine
1
Heparin, Low-Molecular-Weight
1
Gemcitabine
1
Gelsolin
1
Etanercept
1
Dexamethasone
1
Contrast Media
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cytokine Release Syndrome
×
Neuropsychological Tests
×
Clear all
NCT05510596
2024-08-09
MR-ICANS
University Hospital, Montpellier
Phase NA
Completed
25 enrolled